This paper is in the following e-collection/theme issue:

Opioid and Related Substance Abuse Crisis (84) JMIR Theme Issue: COVID-19 Special Issue (2241) Outbreak and Pandemic Preparedness and Management (1529) Infectious Diseases (non-STD/STI) (1288) Health Care Quality and Health Services Research (160)

Published on in Vol 7 , No 5 (2021) :May

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/29298, first published .
Increases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series Study

Increases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series Study

Increases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series Study

Authors of this article:

Dalia Khoury 1 Author Orcid Image ;   Alexander Preiss 1 Author Orcid Image ;   Paul Geiger 1 Author Orcid Image ;   Mohd Anwar 2 Author Orcid Image ;   Kevin Paul Conway 3 Author Orcid Image
Article Authors Cited by (18) Tweetations (7) Metrics

Journals

  1. Carter A, Soucier D, Haram E, Mazerolle S, Sauschuck M, Coutu-Farrell K. Maine's Overdose Prevention Through Intensive Outreach, Naloxone and Safety (OPTIONS) Initiative. Journal of Public Health Management and Practice 2022;28(Supplement 6):S326 View
  2. Gill E, Ghimire A, Robinett D, Booth J, Walter L. Pregnancy, Opioid Use Disorder and COVID-19: An Evaluation of Acute Care Presentations During a Pandemic. Journal of Addiction Medicine 2022;Publish Ahead of Print View
  3. Ward M, Gwanzura T, Rojas R, Trepka M, Bursac Z, Wagner E. Nonfatal opioid-related overdoses treated by emergency medical services in Florida, before and during the COVID-19 pandemic. Preventive Medicine Reports 2023;31:102102 View
  4. . Higher-Dose Naloxone Nasal Spray (Kloxxado) for Opioid Overdose. JAMA 2021;326(18):1853 View
  5. Vallecillo G, Fonseca F, Oviedo L, Durán X, Martinez I, García-Guix A, Castillo C, Torrens M, Llana S, Roquer A, Martinez M, Aguelo S, Canosa I. Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical care. Drug and Alcohol Dependence Reports 2022;2:100027 View
  6. Feder K, Choi J, Schluth C, Hayashi K, DeBeck K, Milloy M, Kirk G, Mehta S, Kipke M, Moore R, Baum M, Shoptaw S, Gorbach P, Mustanski B, Javanbakht M, Siminski S, Genberg B. Factors associated with self-reported avoidance of harm reduction services during the COVID-19 pandemic by people who use drugs in five cities in the United States and Canada. Drug and Alcohol Dependence 2022;241:109544 View
  7. Vo A, Patton T, Peacock A, Larney S, Borquez A. Illicit Substance Use and the COVID-19 Pandemic in the United States: A Scoping Review and Characterization of Research Evidence in Unprecedented Times. International Journal of Environmental Research and Public Health 2022;19(14):8883 View
  8. Hughes T, Kalicki A, Huxley-Reicher Z, Toribio W, Samuels D, Weiss J, Herscher M, Wang L. A medical student-led model for telephone-based opioid overdose education and naloxone distribution during the COVID-19 pandemic. Substance Abuse 2022;43(1):988 View
  9. Courtney J, Kreys E, Luu B, Kreys T, Vinall R, Quang V, Titus-Lay E. Effectiveness of an Advanced Naloxone Training, Simulation, and Assessment of Second-Year Pharmacy Students. Pharmacy 2022;10(6):153 View
  10. Haggerty T, Khodaverdi M, Dekeseredy P, Wood N, Hendricks B, Peklinsky J, Sedney C. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia. Journal of Substance Abuse Treatment 2022;136:108687 View
  11. Conway K, Khoury D, Hilscher R, Aldridge A, Parker S, Zarkin G. Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018. Addiction Science & Clinical Practice 2022;17(1) View
  12. Downs A, McElligott Z. Noradrenergic circuits and signaling in substance use disorders. Neuropharmacology 2022;208:108997 View
  13. Bass S, Kelly P, Pandit-Kerr S, Pilla J, Morris K, Larsen E, Wisdom J, Torralva P. “It's my frenemy”: A qualitative exploration of knowledge and perceptions of fentanyl use during the COVID-19 pandemic in people who use drugs at a syringe services program in Philadelphia, PA. Frontiers in Public Health 2022;10 View
  14. Wightman R, Nelson L. Naloxone Dosing in the Era of Fentanyl: The Path Widens by Traveling Down It. Annals of Emergency Medicine 2022;80(2):127 View
  15. Mathias C, Cavazos D, McGlothen-Bell K, Crawford A, Flowers-Joseph B, Wang Z, Cleveland L. Opioid overdose prevention education in Texas during the COVID-19 pandemic. Harm Reduction Journal 2023;20(1) View
  16. Bodnar R. Endogenous opiates and behavior: 2021. Peptides 2023;164:171004 View
  17. Bedard M, Lord J, Perez P, Bravo I, Teklezghi A, Tarantino L, Diering G, McElligott Z. Probing different paradigms of morphine withdrawal on sleep behavior in male and female C57BL/6J mice. Behavioural Brain Research 2023;448:114441 View
  18. Bedard M, Nowlan A, Martin del Campo Z, Miller C, Dasgupta N, McElligott Z. All Hands on Deck: We Need Multiple Approaches To Uncover the Neuroscience behind the Opioid Overdose Crisis. ACS Chemical Neuroscience 2023 View